The Efficacy, Safety, and Tolerability of Levofloxacin Quadruple Therapy for Helicobacter pylori Eradication: A Randomized, Double-Blind Clinical Trial

Table 3

The adverse drug reactions associated with the BPAL-7 and BPAL-10 regimens.

ADRs	BPAL-7 (n = 107)			BPAL-10 (n = 109)
	Mild	Moderate	Severe	Mild	Moderate	Severe
Pyrosis	31 (29.0)	4 (3.7)	1 (0.9)	23 (21.1)	10 (9.2)	1 (0.9)
Anorexia	25 (23.4)	4 (3.7)	2 (1.9)	21 (19.3)	4 (3.7)	1 (0.9)
Nausea	19 (17.8)	2 (1.8)	1 (0.9)	25 (22.9)	0 (0.0)	0 (0.0)
Vomiting	2 (1.9)	1 (0.9)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.9)
Bitter taste	19 (17.8)	0 (0.0)	1 (0.9)	10 (9.2)	2 (1.8)	1 (0.9)
Abdominal colic	12 (11.2)	0 (0.0)	0 (0.0)	9 (8.2)	3 (2.7)	0 (0.0)
Epigastric pain	17 (15.9)	7 (6.5)	1 (0.9)	22 (20.2)	3 (2.7)	1 (0.9)
Headache	15 (14.0)	2 (1.9)	1 (0.9)	16 (14.7)	7 (6.4)	1 (0.9)
Back pain	6 (5.6)	1 (0.9)	2 (1.9)	9 (8.3)	6 (5.5)	1 (0.9)

Values were demonstrated as numbers (percentages). Adverse drug reactions were evaluated during the study. Chi-square test was performed to compare variables between groups. None of variables were shown statistically significant differences between two regimens in each category. ADRs: adverse drug reactions; BPAL-7 and BPAL-10: bismuth-based quadruple therapies containing pantoprazole, amoxicillin, and levofloxacin for seven and ten days, respectively.